Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro
Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggre...
Saved in:
Published in | Journal of experimental & clinical cancer research Vol. 31; no. 1; p. 32 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
02.04.2012
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer.
Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured.
We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration.
Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role. |
---|---|
AbstractList | Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer.
Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured.
We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration.
Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role. BACKGROUND: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. METHODS: Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. RESULTS: We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. CONCLUSIONS: Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role. Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer.BACKGROUNDObesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer.Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured.METHODSSupernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured.We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration.RESULTSWe show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration.Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.CONCLUSIONSOur findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role. Doc number: 32 Abstract Background: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. Methods: Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. Results: We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. Conclusions: Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role. Abstract Background Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. Methods Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. Results We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. Conclusions Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role. |
ArticleNumber | 32 |
Author | Monteiro, Cátia Cunha, Virgínia Príncipe, Paulo Mota-Pinto, Anabela Lopes, Carlos Fraga, Avelino Sanches-Magalhães, José Lobato, Carlos Lobo, Francisco Pina, Francisco Ribeiro, Ricardo Oliveira, Jorge Oliveira, Maria José Morais, António Silva, Vítor Freitas, Mariana Medeiros, Rui |
AuthorAffiliation | 6 General Pathology Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal 13 Molecular Oncology Group - CI, Portuguese Institute of Oncology, Porto Centre, Edifício Laboratórios - Piso 4, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal 12 Urology Department, S. João Hospital, Porto, Portugal 10 Urology Department, Porto Military Hospital, Porto, Portugal 7 CIMAGO, Centre of Investigation in Environment, Genetics and Oncobiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal 4 Biomaterials Division, NEWTherapies Group, INEB, Porto, Portugal 8 CNC, Centre of Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal 11 Urology Department, Portuguese Institute of Oncology, Porto, Portugal 9 Urology Department, Porto Hospital Centre, Porto, Portugal 1 Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal 3 Research Department-Portuguese League Against Cancer (NRNorte), LPCC, Porto, Portugal 2 Abel Salazar Biomedic |
AuthorAffiliation_xml | – name: 4 Biomaterials Division, NEWTherapies Group, INEB, Porto, Portugal – name: 9 Urology Department, Porto Hospital Centre, Porto, Portugal – name: 10 Urology Department, Porto Military Hospital, Porto, Portugal – name: 13 Molecular Oncology Group - CI, Portuguese Institute of Oncology, Porto Centre, Edifício Laboratórios - Piso 4, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal – name: 2 Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal – name: 6 General Pathology Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal – name: 1 Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal – name: 11 Urology Department, Portuguese Institute of Oncology, Porto, Portugal – name: 3 Research Department-Portuguese League Against Cancer (NRNorte), LPCC, Porto, Portugal – name: 7 CIMAGO, Centre of Investigation in Environment, Genetics and Oncobiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal – name: 8 CNC, Centre of Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal – name: 12 Urology Department, S. João Hospital, Porto, Portugal – name: 5 Department of Pathology and Oncology, Faculty of Medicine, Porto, Portugal |
Author_xml | – sequence: 1 givenname: Ricardo surname: Ribeiro fullname: Ribeiro, Ricardo – sequence: 2 givenname: Cátia surname: Monteiro fullname: Monteiro, Cátia – sequence: 3 givenname: Virgínia surname: Cunha fullname: Cunha, Virgínia – sequence: 4 givenname: Maria José surname: Oliveira fullname: Oliveira, Maria José – sequence: 5 givenname: Mariana surname: Freitas fullname: Freitas, Mariana – sequence: 6 givenname: Avelino surname: Fraga fullname: Fraga, Avelino – sequence: 7 givenname: Paulo surname: Príncipe fullname: Príncipe, Paulo – sequence: 8 givenname: Carlos surname: Lobato fullname: Lobato, Carlos – sequence: 9 givenname: Francisco surname: Lobo fullname: Lobo, Francisco – sequence: 10 givenname: António surname: Morais fullname: Morais, António – sequence: 11 givenname: Vítor surname: Silva fullname: Silva, Vítor – sequence: 12 givenname: José surname: Sanches-Magalhães fullname: Sanches-Magalhães, José – sequence: 13 givenname: Jorge surname: Oliveira fullname: Oliveira, Jorge – sequence: 14 givenname: Francisco surname: Pina fullname: Pina, Francisco – sequence: 15 givenname: Anabela surname: Mota-Pinto fullname: Mota-Pinto, Anabela – sequence: 16 givenname: Carlos surname: Lopes fullname: Lopes, Carlos – sequence: 17 givenname: Rui surname: Medeiros fullname: Medeiros, Rui |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22469146$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1v1DAQhiNURD_gzA1F4sIlNOOv2BckqFpaqRIH4Gw5zmTxKrEXO1mJf4_TXVbdip7Gmnnn0TueOS9OfPBYFG-h_gggxSU0XFRKCVFRqCh5UZwdMieP3qfFeUrruhagQL0qTglhQgETZ8X323k0vtxgdJsY0mQmZ0vTuU1IWE4upRnLXBjDhKncK7C0xluMpVmtIqbktuhzKJ0vt26K4XXxsjdDwjf7eFH8vLn-cXVb3X_7enf1-b5qhSRTJQ3K2hLbNy3hfce5lILXDROmF9BQzq2VLVBam1Z12TDreEM4bTk2HbPS0IvibsftglnrTXSjiX90ME4_JEJcaRPzPAPqHhqpsOsF7RjrgbWUMUWskYz2kgnMrE871mZuR-ws-ima4Qh6XPHul16Fraa0UYrVGfBlB2hdeAZwXLFh1MuC9LIgTUFTkiEf9i5i-D1jmvToksVhMB7DnDTUBJQEIhfp-yfSdZijz__9oAJBQEJWvXs81sHOvwPIgsudwObdpoj9QQK1Xk7sPx75kw7rlrMJy1hueLbvL6551ZA |
CitedBy_id | crossref_primary_10_1016_j_bbalip_2013_02_010 crossref_primary_10_3390_cancers13215537 crossref_primary_10_1371_journal_pone_0123217 crossref_primary_10_3390_cancers14071679 crossref_primary_10_1038_s41598_021_97539_2 crossref_primary_10_1016_j_jnutbio_2014_11_001 crossref_primary_10_1186_s13148_018_0490_3 crossref_primary_10_1186_s13046_015_0178_x crossref_primary_10_1007_s11690_014_0421_1 crossref_primary_10_1158_1541_7786_MCR_18_0748 crossref_primary_10_1111_andr_12331 crossref_primary_10_3390_cells12050802 crossref_primary_10_1007_s10495_017_1366_2 crossref_primary_10_4110_in_2018_18_e47 crossref_primary_10_1186_1741_7015_10_108 crossref_primary_10_1007_s10555_022_10056_0 crossref_primary_10_1186_1741_7015_10_109 crossref_primary_10_4103_tcmj_tcmj_62_22 crossref_primary_10_1186_s12894_017_0201_y crossref_primary_10_1016_j_bcp_2024_116097 crossref_primary_10_1016_j_heliyon_2024_e30807 crossref_primary_10_1016_j_clgc_2013_07_013 crossref_primary_10_1002_stem_1857 crossref_primary_10_1016_j_clinbiochem_2012_12_012 crossref_primary_10_18632_oncotarget_11712 crossref_primary_10_1530_ERC_17_0466 crossref_primary_10_1186_1748_717X_9_93 crossref_primary_10_23902_trkjnat_978266 crossref_primary_10_1530_ERC_15_0556 crossref_primary_10_3892_ol_2024_14617 crossref_primary_10_1007_s40618_020_01294_6 crossref_primary_10_1590_1414_431x2024e13351 crossref_primary_10_4111_icu_20230215 crossref_primary_10_1155_2018_9247864 crossref_primary_10_1016_j_phrs_2018_02_022 crossref_primary_10_1002_jmri_24824 crossref_primary_10_1007_s10147_019_01559_y crossref_primary_10_18632_oncotarget_10258 crossref_primary_10_12677_HJBM_2023_134046 crossref_primary_10_3390_ijms231810762 crossref_primary_10_1002_2211_5463_12976 crossref_primary_10_3390_ijms22094469 crossref_primary_10_1016_j_cytogfr_2017_11_002 crossref_primary_10_1515_hmbci_2015_0075 crossref_primary_10_3390_ijms24021229 crossref_primary_10_1002_pros_24117 crossref_primary_10_1038_s41585_023_00764_9 crossref_primary_10_1038_s41598_017_04951_8 crossref_primary_10_3389_fcell_2020_571648 crossref_primary_10_1016_j_canlet_2016_06_010 crossref_primary_10_1258_ebm_2012_012131 crossref_primary_10_1038_ncomms10230 crossref_primary_10_1002_pros_23158 crossref_primary_10_1186_s12885_024_13207_4 crossref_primary_10_1364_BOE_537783 crossref_primary_10_1289_ehp_1510090 crossref_primary_10_3389_fped_2014_00053 crossref_primary_10_3892_ol_2017_7454 crossref_primary_10_1007_s13277_013_1268_z crossref_primary_10_1051_medsci_20163206012 crossref_primary_10_1007_s13277_016_5198_4 crossref_primary_10_1186_s12967_024_05458_3 crossref_primary_10_3390_cancers12092718 crossref_primary_10_1002_pros_22756 crossref_primary_10_3390_cancers14205077 crossref_primary_10_18632_aging_205065 crossref_primary_10_3390_cancers10120523 crossref_primary_10_1038_s41430_020_00713_4 crossref_primary_10_3390_jpm10040185 crossref_primary_10_18632_oncotarget_18038 crossref_primary_10_3390_biomedicines9111692 crossref_primary_10_1158_1055_9965_EPI_14_0236 crossref_primary_10_1016_j_urology_2016_07_042 crossref_primary_10_1016_j_actbio_2021_04_041 crossref_primary_10_3390_cancers12061385 crossref_primary_10_1111_bju_14173 crossref_primary_10_3390_nu7042539 crossref_primary_10_3390_cancers17030372 crossref_primary_10_1186_1756_9966_32_56 crossref_primary_10_1002_cam4_70001 crossref_primary_10_3390_cancers16152769 crossref_primary_10_3390_ijms242015140 crossref_primary_10_1016_j_isci_2022_104056 crossref_primary_10_1080_01635581_2019_1633363 crossref_primary_10_1016_j_phrs_2020_104741 crossref_primary_10_1371_journal_pone_0091069 crossref_primary_10_1016_j_lfs_2023_122225 crossref_primary_10_1186_s13046_015_0127_8 crossref_primary_10_3892_ol_2019_10555 crossref_primary_10_3390_metabo11110765 crossref_primary_10_2131_jts_40_21 crossref_primary_10_1186_1756_9966_33_31 crossref_primary_10_1080_13685538_2018_1519695 crossref_primary_10_4137_LPI_S10871 crossref_primary_10_3389_fphar_2021_626155 crossref_primary_10_1002_pros_24054 crossref_primary_10_1016_j_juro_2013_06_050 crossref_primary_10_1080_01635581_2020_1856889 crossref_primary_10_1002_cbf_3979 crossref_primary_10_1530_EC_19_0029 crossref_primary_10_1530_ERC_18_0058 crossref_primary_10_3389_fphar_2023_1145860 crossref_primary_10_1002_ijc_31775 crossref_primary_10_1038_s41598_024_71862_w crossref_primary_10_18632_oncotarget_6643 crossref_primary_10_1016_j_jab_2014_09_004 crossref_primary_10_1007_s13277_013_1439_y crossref_primary_10_1186_1756_9966_32_77 crossref_primary_10_2214_AJR_14_12689 crossref_primary_10_18632_oncotarget_11131 |
Cites_doi | 10.1111/j.1467-789X.2011.00917.x 10.1111/j.1464-410X.2008.07534.x 10.1038/nrc3174 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T 10.1038/sj.pcan.4500844 10.1038/sj.ijo.0803632 10.1016/j.bbrc.2006.03.044 10.1002/pros.21029 10.1158/0008-5472.CAN-05-1231 10.1038/pcan.2009.11 10.1007/978-1-59745-245-8_14 10.1001/jama.293.17.2095 10.1074/jbc.M301158200 10.1128/MCB.01275-09 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H 10.1002/pros.2990220307 10.1016/j.canlet.2003.09.016 10.1111/j.1464-410X.2010.09811.x 10.1371/journal.pone.0013612 10.1111/j.1464-410X.2011.10453.x 10.1016/j.yexmp.2005.08.004 10.1158/0008-5472.CAN-10-3323 10.1152/ajpendo.00127.2007 10.1111/j.1365-201X.2005.01468.x 10.1158/1055-9965.EPI-09-0372 10.1016/j.bbrc.2006.07.139 10.1007/s00424-009-0693-8 10.1083/jcb.105.5.2409 10.1210/er.2010-0030 10.1016/j.juro.2009.06.015 10.1038/nm.2492 10.1002/(SICI)1097-0142(19991101)86:9<1775::AID-CNCR20>3.0.CO;2-L 10.1080/019021490944232 10.1172/JCI31791 10.1006/bbrc.1996.0178 10.1152/ajpendo.90316.2008 10.1111/j.1349-7006.2011.01861.x 10.1161/01.CIR.0000121425.42966.F1 10.4161/org.5.2.8347 10.1016/0006-291X(90)91449-3 10.1210/jc.2009-2623 10.1161/01.ATV.19.10.2323 10.1371/journal.pone.0027851 10.1152/physiol.00009.2005 10.1007/BF00689790 10.1046/j.1464-410X.2003.04218.x 10.1016/j.cell.2011.09.024 10.1016/S0022-5347(05)67318-1 10.1128/JCM.00667-10 10.1074/jbc.M709401200 10.1074/jbc.M304984200 10.1007/s00394-009-0775-6 10.1016/j.eururo.2007.03.054 10.1159/000337604 10.1007/s11745-011-3630-5 10.1097/01.ju.0000141582.15218.10 10.1002/jcp.22455 10.1006/bbrc.1999.0515 10.1016/j.peptides.2009.10.001 10.1038/nrc745 10.1016/S0022-4804(03)00166-5 10.1046/j.1432-0436.2002.700905.x |
ContentType | Journal Article |
Copyright | 2012 Ribeiro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2012 Ribeiro et al; licensee BioMed Central Ltd. 2012 Ribeiro et al; licensee BioMed Central Ltd. |
Copyright_xml | – notice: 2012 Ribeiro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2012 Ribeiro et al; licensee BioMed Central Ltd. 2012 Ribeiro et al; licensee BioMed Central Ltd. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/1756-9966-31-32 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 32 |
ExternalDocumentID | oai_doaj_org_article_f1789edf63d44f14b34492ca843f846e PMC3379940 oai_biomedcentral_com_1756_9966_31_32 2691878671 22469146 10_1186_1756_9966_31_32 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 0R~ 29K 2VQ 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO -5E -5G -A0 -BR ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM |
ID | FETCH-LOGICAL-b682t-8ae80c2cf7b25fd5588650746af617355cc8b1330ab9d2464d57253b5e7d4c8a3 |
IEDL.DBID | RBZ |
ISSN | 1756-9966 0392-9078 |
IngestDate | Wed Aug 27 01:30:32 EDT 2025 Thu Aug 21 18:21:45 EDT 2025 Wed May 22 07:15:40 EDT 2024 Sun Aug 24 04:10:05 EDT 2025 Fri Jul 25 01:10:11 EDT 2025 Thu Apr 03 06:55:19 EDT 2025 Thu Apr 24 22:53:15 EDT 2025 Tue Jul 01 02:26:23 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b682t-8ae80c2cf7b25fd5588650746af617355cc8b1330ab9d2464d57253b5e7d4c8a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-News-3 content type line 23 |
OpenAccessLink | http://dx.doi.org/10.1186/1756-9966-31-32 |
PMID | 22469146 |
PQID | 1021162181 |
PQPubID | 105475 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f1789edf63d44f14b34492ca843f846e pubmedcentral_primary_oai_pubmedcentral_nih_gov_3379940 biomedcentral_primary_oai_biomedcentral_com_1756_9966_31_32 proquest_miscellaneous_1021981282 proquest_journals_1021162181 pubmed_primary_22469146 crossref_primary_10_1186_1756_9966_31_32 crossref_citationtrail_10_1186_1756_9966_31_32 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-04-02 |
PublicationDateYYYYMMDD | 2012-04-02 |
PublicationDate_xml | – month: 04 year: 2012 text: 2012-04-02 day: 02 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of experimental & clinical cancer research |
PublicationTitleAlternate | J Exp Clin Cancer Res |
PublicationYear | 2012 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | M Iwamura (569_CR34) 1993; 22 SY Sung (569_CR64) 2002; 70 J Chen (569_CR43) 2011; 12 T Mistry (569_CR29) 2007; 52 DP Chopra (569_CR36) 2004; 203 RC van Kruijsdijk (569_CR2) 2009; 18 D Desbois (569_CR17) 2010; 48 JM Wang (569_CR54) 1990; 169 J Park (569_CR1) 2011; 32 JG van Roermund (569_CR8) 2011; 107 L Cheng (569_CR5) 1999; 86 CY Lin (569_CR26) 2011; 102 TD Chung (569_CR32) 1999; 38 G Ferry (569_CR55) 2003; 278 S Chakrabarti (569_CR25) 2005; 31 M Zeyda (569_CR39) 2007; 31 JL Mohler (569_CR42) 1993; 12 PC Albertsen (569_CR18) 2005; 293 T Mistry (569_CR37) 2006; 348 CY Huang (569_CR47) 2011; 226 M Takahashi (569_CR50) 1996; 219 RJ Ribeiro (569_CR15) 2012; 29 SJ Freedland (569_CR4) 2009; 12 M Kinoshita (569_CR51) 1999; 19 Y Tokuda (569_CR13) 2003; 91 A Wells (569_CR44) 1998; 43 DS Finley (569_CR7) 2009; 182 A Mizokami (569_CR35) 2000; 164 S Kharait (569_CR41) 2006; 343 S Toda (569_CR63) 2009; 5 Y Wu (569_CR60) 2008; 295 J Azare (569_CR56) 2011; 6 EH Allott (569_CR27) 2011 MR Hoda (569_CR31) 2008; 102 B Dirat (569_CR11) 2011; 71 RS Taichman (569_CR19) 2007; 117 ST Patel (569_CR61) 2010; 31 B Desai (569_CR45) 2008; 283 R Unal (569_CR22) 2010; 95 DH Geho (569_CR57) 2005; 20 E Maury (569_CR40) 2007; 293 P Somasundar (569_CR14) 2003; 113 S Thalmann (569_CR16) 2008; 456 U Capitanio (569_CR3) 2011; 109 M Notarnicola (569_CR21) 2012; 47 V Subramaniam (569_CR46) 2005; 79 J Rehman (569_CR38) 2004; 109 KL Andarawewa (569_CR62) 2005; 65 G Taraboletti (569_CR53) 1987; 105 KM Nieman (569_CR9) 2011; 17 S Mori (569_CR33) 1999; 257 A O'Hara (569_CR59) 2009; 458 MV Hoang (569_CR52) 2010; 5 M Onuma (569_CR12) 2003; 278 CH Tang (569_CR48) 2009; 69 M Egeblad (569_CR23) 2002; 2 MJ Khandekar (569_CR58) 2011; 11 K Schnabele (569_CR10) 2009; 48 P Trayhurn (569_CR28) 2005; 184 S Valastyan (569_CR6) 2011; 147 LW Chung (569_CR20) 2005; 173 R Lichtinghagen (569_CR24) 2003; 23 E Im (569_CR49) 2010; 30 R Ribeiro (569_CR30) 2006; 9 15888576 - Physiology (Bethesda). 2005 Jun;20:194-200 12699491 - BJU Int. 2003 May;91(7):716-20 19819277 - Peptides. 2010 Jan;31(1):51-7 21049044 - PLoS One. 2010;5(10):e13612 3680388 - J Cell Biol. 1987 Nov;105(5):2409-15 17593905 - Int J Obes (Lond). 2007 Sep;31(9):1420-8 15592017 - J Urol. 2005 Jan;173(1):10-20 11990853 - Nat Rev Cancer. 2002 Mar;2(3):161-74 16322233 - Cancer Res. 2005 Dec 1;65(23):10862-71 21459803 - Cancer Res. 2011 Apr 1;71(7):2455-65 16344847 - Prostate Cancer Prostatic Dis. 2006;9(1):19-24 19169726 - Eur J Nutr. 2009 Apr;48(3):154-61 12894549 - Anticancer Res. 2003 May-Jun;23(3B):2617-24 21777363 - BJU Int. 2012 Mar;109(5):678-84 21219539 - Cancer Sci. 2011 Apr;102(4):815-27 16564022 - Biochem Biophys Res Commun. 2006 May 12;343(3):848-56 17786228 - J Clin Invest. 2007 Sep;117(9):2351-61 16019990 - Exp Lung Res. 2005 Jul-Aug;31(6):599-621 18492766 - Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E205-15 20392866 - J Clin Endocrinol Metab. 2010 Jun;95(6):2993-3001 14993122 - Circulation. 2004 Mar 16;109(10):1292-8 22140473 - PLoS One. 2011;6(11):e27851 10198259 - Biochem Biophys Res Commun. 1999 Apr 13;257(2):609-14 15870412 - JAMA. 2005 May 4;293(17):2095-101 12492493 - Differentiation. 2002 Dec;70(9-10):506-21 8619824 - Biochem Biophys Res Commun. 1996 Feb 6;219(1):40-6 22090062 - Lipids. 2012 Jan;47(1):59-63 12902351 - J Biol Chem. 2003 Oct 24;278(43):42660-7 19755644 - Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2569-78 16026420 - Acta Physiol Scand. 2005 Aug;184(4):285-93 17578888 - Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E656-65 21050356 - BJU Int. 2011 Jun;107(11):1775-9 19683746 - J Urol. 2009 Oct;182(4):1621-7 10068344 - Prostate. 1999 Feb 15;38(3):199-207 20231358 - Mol Cell Biol. 2010 May;30(10):2401-10 20945385 - J Cell Physiol. 2011 May;226(5):1274-82 22113164 - Nat Rev Cancer. 2011 Dec;11(12):886-95 12943810 - J Surg Res. 2003 Jul;113(1):50-5 10953159 - J Urol. 2000 Sep;164(3 Pt 1):800-5 10521360 - Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2323-9 19585142 - Pflugers Arch. 2009 Oct;458(6):1103-14 14732222 - Cancer Lett. 2004 Jan 20;203(2):145-54 17399889 - Eur Urol. 2007 Jul;52(1):46-53 22415092 - Cell Physiol Biochem. 2012;29(1-2):233-40 8488157 - Prostate. 1993;22(3):243-52 18337256 - J Biol Chem. 2008 May 16;283(20):13856-66 10547551 - Cancer. 1999 Nov 1;86(9):1775-82 19676095 - Prostate. 2009 Dec 1;69(16):1781-9 22000009 - Cell. 2011 Oct 14;147(2):275-92 18516562 - Methods Mol Biol. 2008;456:195-9 21642230 - Endocr Rev. 2011 Aug;32(4):550-70 18341625 - BJU Int. 2008 Aug;102(3):383-8 22093240 - Obes Rev. 2011 Dec;12(12):1063-70 22121096 - Mol Carcinog. 2013 Feb;52(2):144-54 9858337 - Microsc Res Tech. 1998 Dec 1;43(5):395-411 12642576 - J Biol Chem. 2003 May 16;278(20):18162-9 2190552 - Biochem Biophys Res Commun. 1990 May 31;169(1):165-70 19794899 - Organogenesis. 2009 Apr;5(2):50-6 16229833 - Exp Mol Pathol. 2005 Dec;79(3):187-93 20592136 - J Clin Microbiol. 2010 Sep;48(9):3306-15 8448827 - Cancer Metastasis Rev. 1993 Mar;12(1):53-67 19581922 - Prostate Cancer Prostatic Dis. 2009;12(3):259-63 22037646 - Nat Med. 2011;17(11):1498-503 16899222 - Biochem Biophys Res Commun. 2006 Sep 29;348(3):832-8 |
References_xml | – volume: 12 start-page: 1063 year: 2011 ident: 569_CR43 publication-title: Obes Rev doi: 10.1111/j.1467-789X.2011.00917.x – volume: 102 start-page: 383 year: 2008 ident: 569_CR31 publication-title: BJU Int doi: 10.1111/j.1464-410X.2008.07534.x – volume: 11 start-page: 886 year: 2011 ident: 569_CR58 publication-title: Nat Rev Cancer doi: 10.1038/nrc3174 – volume: 43 start-page: 395 year: 1998 ident: 569_CR44 publication-title: Microsc Res Tech doi: 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T – volume: 9 start-page: 19 year: 2006 ident: 569_CR30 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/sj.pcan.4500844 – volume: 31 start-page: 1420 year: 2007 ident: 569_CR39 publication-title: Int J Obes (Lond) doi: 10.1038/sj.ijo.0803632 – volume: 343 start-page: 848 year: 2006 ident: 569_CR41 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.03.044 – volume: 69 start-page: 1781 year: 2009 ident: 569_CR48 publication-title: Prostate doi: 10.1002/pros.21029 – volume: 65 start-page: 10862 year: 2005 ident: 569_CR62 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1231 – volume: 12 start-page: 259 year: 2009 ident: 569_CR4 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2009.11 – volume: 456 start-page: 195 year: 2008 ident: 569_CR16 publication-title: Methods Mol Biol doi: 10.1007/978-1-59745-245-8_14 – volume: 293 start-page: 2095 year: 2005 ident: 569_CR18 publication-title: JAMA doi: 10.1001/jama.293.17.2095 – volume: 278 start-page: 18162 year: 2003 ident: 569_CR55 publication-title: J Biol Chem doi: 10.1074/jbc.M301158200 – volume: 30 start-page: 2401 year: 2010 ident: 569_CR49 publication-title: Mol Cell Biol doi: 10.1128/MCB.01275-09 – volume: 38 start-page: 199 year: 1999 ident: 569_CR32 publication-title: Prostate doi: 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H – volume: 22 start-page: 243 year: 1993 ident: 569_CR34 publication-title: Prostate doi: 10.1002/pros.2990220307 – volume: 203 start-page: 145 year: 2004 ident: 569_CR36 publication-title: Cancer Lett doi: 10.1016/j.canlet.2003.09.016 – volume: 107 start-page: 1775 year: 2011 ident: 569_CR8 publication-title: BJU Int doi: 10.1111/j.1464-410X.2010.09811.x – volume: 5 start-page: e13612 year: 2010 ident: 569_CR52 publication-title: PLoS One doi: 10.1371/journal.pone.0013612 – volume: 109 start-page: 678 year: 2011 ident: 569_CR3 publication-title: BJU Int doi: 10.1111/j.1464-410X.2011.10453.x – volume: 79 start-page: 187 year: 2005 ident: 569_CR46 publication-title: Exp Mol Pathol doi: 10.1016/j.yexmp.2005.08.004 – volume: 71 start-page: 2455 year: 2011 ident: 569_CR11 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-3323 – volume: 293 start-page: E656 year: 2007 ident: 569_CR40 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00127.2007 – volume: 184 start-page: 285 year: 2005 ident: 569_CR28 publication-title: Acta Physiol Scand doi: 10.1111/j.1365-201X.2005.01468.x – volume: 18 start-page: 2569 year: 2009 ident: 569_CR2 publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-09-0372 – volume: 348 start-page: 832 year: 2006 ident: 569_CR37 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.07.139 – volume-title: Mol Carcinog year: 2011 ident: 569_CR27 – volume: 458 start-page: 1103 year: 2009 ident: 569_CR59 publication-title: Pflugers Arch doi: 10.1007/s00424-009-0693-8 – volume: 105 start-page: 2409 year: 1987 ident: 569_CR53 publication-title: J Cell Biol doi: 10.1083/jcb.105.5.2409 – volume: 32 start-page: 550 year: 2011 ident: 569_CR1 publication-title: Endocr Rev doi: 10.1210/er.2010-0030 – volume: 182 start-page: 1621 year: 2009 ident: 569_CR7 publication-title: J Urol doi: 10.1016/j.juro.2009.06.015 – volume: 17 start-page: 1498 year: 2011 ident: 569_CR9 publication-title: Nat Med doi: 10.1038/nm.2492 – volume: 86 start-page: 1775 year: 1999 ident: 569_CR5 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19991101)86:9<1775::AID-CNCR20>3.0.CO;2-L – volume: 31 start-page: 599 year: 2005 ident: 569_CR25 publication-title: Exp Lung Res doi: 10.1080/019021490944232 – volume: 117 start-page: 2351 year: 2007 ident: 569_CR19 publication-title: J Clin Invest doi: 10.1172/JCI31791 – volume: 219 start-page: 40 year: 1996 ident: 569_CR50 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1996.0178 – volume: 295 start-page: E205 year: 2008 ident: 569_CR60 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.90316.2008 – volume: 102 start-page: 815 year: 2011 ident: 569_CR26 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2011.01861.x – volume: 109 start-page: 1292 year: 2004 ident: 569_CR38 publication-title: Circulation doi: 10.1161/01.CIR.0000121425.42966.F1 – volume: 5 start-page: 50 year: 2009 ident: 569_CR63 publication-title: Organogenesis doi: 10.4161/org.5.2.8347 – volume: 169 start-page: 165 year: 1990 ident: 569_CR54 publication-title: Biochem Biophys Res Commun doi: 10.1016/0006-291X(90)91449-3 – volume: 95 start-page: 2993 year: 2010 ident: 569_CR22 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-2623 – volume: 23 start-page: 2617 year: 2003 ident: 569_CR24 publication-title: Anticancer Res – volume: 19 start-page: 2323 year: 1999 ident: 569_CR51 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.19.10.2323 – volume: 6 start-page: e27851 year: 2011 ident: 569_CR56 publication-title: PLoS One doi: 10.1371/journal.pone.0027851 – volume: 20 start-page: 194 year: 2005 ident: 569_CR57 publication-title: Physiology (Bethesda) doi: 10.1152/physiol.00009.2005 – volume: 12 start-page: 53 year: 1993 ident: 569_CR42 publication-title: Cancer Metastasis Rev doi: 10.1007/BF00689790 – volume: 91 start-page: 716 year: 2003 ident: 569_CR13 publication-title: BJU Int doi: 10.1046/j.1464-410X.2003.04218.x – volume: 147 start-page: 275 year: 2011 ident: 569_CR6 publication-title: Cell doi: 10.1016/j.cell.2011.09.024 – volume: 164 start-page: 800 year: 2000 ident: 569_CR35 publication-title: J Urol doi: 10.1016/S0022-5347(05)67318-1 – volume: 48 start-page: 3306 year: 2010 ident: 569_CR17 publication-title: J Clin Microbiol doi: 10.1128/JCM.00667-10 – volume: 283 start-page: 13856 year: 2008 ident: 569_CR45 publication-title: J Biol Chem doi: 10.1074/jbc.M709401200 – volume: 278 start-page: 42660 year: 2003 ident: 569_CR12 publication-title: J Biol Chem doi: 10.1074/jbc.M304984200 – volume: 48 start-page: 154 year: 2009 ident: 569_CR10 publication-title: Eur J Nutr doi: 10.1007/s00394-009-0775-6 – volume: 52 start-page: 46 year: 2007 ident: 569_CR29 publication-title: Eur Urol doi: 10.1016/j.eururo.2007.03.054 – volume: 29 start-page: 233 year: 2012 ident: 569_CR15 publication-title: Cell Physiol Biochem doi: 10.1159/000337604 – volume: 47 start-page: 59 year: 2012 ident: 569_CR21 publication-title: Lipids doi: 10.1007/s11745-011-3630-5 – volume: 173 start-page: 10 year: 2005 ident: 569_CR20 publication-title: J Urol doi: 10.1097/01.ju.0000141582.15218.10 – volume: 226 start-page: 1274 year: 2011 ident: 569_CR47 publication-title: J Cell Physiol doi: 10.1002/jcp.22455 – volume: 257 start-page: 609 year: 1999 ident: 569_CR33 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1999.0515 – volume: 31 start-page: 51 year: 2010 ident: 569_CR61 publication-title: Peptides doi: 10.1016/j.peptides.2009.10.001 – volume: 2 start-page: 161 year: 2002 ident: 569_CR23 publication-title: Nat Rev Cancer doi: 10.1038/nrc745 – volume: 113 start-page: 50 year: 2003 ident: 569_CR14 publication-title: J Surg Res doi: 10.1016/S0022-4804(03)00166-5 – volume: 70 start-page: 506 year: 2002 ident: 569_CR64 publication-title: Differentiation doi: 10.1046/j.1432-0436.2002.700905.x – reference: 17786228 - J Clin Invest. 2007 Sep;117(9):2351-61 – reference: 16344847 - Prostate Cancer Prostatic Dis. 2006;9(1):19-24 – reference: 20592136 - J Clin Microbiol. 2010 Sep;48(9):3306-15 – reference: 22140473 - PLoS One. 2011;6(11):e27851 – reference: 10953159 - J Urol. 2000 Sep;164(3 Pt 1):800-5 – reference: 19819277 - Peptides. 2010 Jan;31(1):51-7 – reference: 22037646 - Nat Med. 2011;17(11):1498-503 – reference: 10068344 - Prostate. 1999 Feb 15;38(3):199-207 – reference: 15592017 - J Urol. 2005 Jan;173(1):10-20 – reference: 20945385 - J Cell Physiol. 2011 May;226(5):1274-82 – reference: 22093240 - Obes Rev. 2011 Dec;12(12):1063-70 – reference: 18337256 - J Biol Chem. 2008 May 16;283(20):13856-66 – reference: 10198259 - Biochem Biophys Res Commun. 1999 Apr 13;257(2):609-14 – reference: 21642230 - Endocr Rev. 2011 Aug;32(4):550-70 – reference: 22090062 - Lipids. 2012 Jan;47(1):59-63 – reference: 12943810 - J Surg Res. 2003 Jul;113(1):50-5 – reference: 8619824 - Biochem Biophys Res Commun. 1996 Feb 6;219(1):40-6 – reference: 12642576 - J Biol Chem. 2003 May 16;278(20):18162-9 – reference: 12894549 - Anticancer Res. 2003 May-Jun;23(3B):2617-24 – reference: 8488157 - Prostate. 1993;22(3):243-52 – reference: 12492493 - Differentiation. 2002 Dec;70(9-10):506-21 – reference: 22415092 - Cell Physiol Biochem. 2012;29(1-2):233-40 – reference: 15888576 - Physiology (Bethesda). 2005 Jun;20:194-200 – reference: 18516562 - Methods Mol Biol. 2008;456:195-9 – reference: 21050356 - BJU Int. 2011 Jun;107(11):1775-9 – reference: 15870412 - JAMA. 2005 May 4;293(17):2095-101 – reference: 21777363 - BJU Int. 2012 Mar;109(5):678-84 – reference: 19169726 - Eur J Nutr. 2009 Apr;48(3):154-61 – reference: 19585142 - Pflugers Arch. 2009 Oct;458(6):1103-14 – reference: 14993122 - Circulation. 2004 Mar 16;109(10):1292-8 – reference: 11990853 - Nat Rev Cancer. 2002 Mar;2(3):161-74 – reference: 3680388 - J Cell Biol. 1987 Nov;105(5):2409-15 – reference: 18492766 - Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E205-15 – reference: 17578888 - Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E656-65 – reference: 14732222 - Cancer Lett. 2004 Jan 20;203(2):145-54 – reference: 18341625 - BJU Int. 2008 Aug;102(3):383-8 – reference: 8448827 - Cancer Metastasis Rev. 1993 Mar;12(1):53-67 – reference: 2190552 - Biochem Biophys Res Commun. 1990 May 31;169(1):165-70 – reference: 16019990 - Exp Lung Res. 2005 Jul-Aug;31(6):599-621 – reference: 10547551 - Cancer. 1999 Nov 1;86(9):1775-82 – reference: 10521360 - Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2323-9 – reference: 12699491 - BJU Int. 2003 May;91(7):716-20 – reference: 19755644 - Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2569-78 – reference: 21219539 - Cancer Sci. 2011 Apr;102(4):815-27 – reference: 21049044 - PLoS One. 2010;5(10):e13612 – reference: 19794899 - Organogenesis. 2009 Apr;5(2):50-6 – reference: 16564022 - Biochem Biophys Res Commun. 2006 May 12;343(3):848-56 – reference: 19581922 - Prostate Cancer Prostatic Dis. 2009;12(3):259-63 – reference: 19676095 - Prostate. 2009 Dec 1;69(16):1781-9 – reference: 21459803 - Cancer Res. 2011 Apr 1;71(7):2455-65 – reference: 20392866 - J Clin Endocrinol Metab. 2010 Jun;95(6):2993-3001 – reference: 17593905 - Int J Obes (Lond). 2007 Sep;31(9):1420-8 – reference: 22113164 - Nat Rev Cancer. 2011 Dec;11(12):886-95 – reference: 20231358 - Mol Cell Biol. 2010 May;30(10):2401-10 – reference: 22121096 - Mol Carcinog. 2013 Feb;52(2):144-54 – reference: 16322233 - Cancer Res. 2005 Dec 1;65(23):10862-71 – reference: 17399889 - Eur Urol. 2007 Jul;52(1):46-53 – reference: 9858337 - Microsc Res Tech. 1998 Dec 1;43(5):395-411 – reference: 12902351 - J Biol Chem. 2003 Oct 24;278(43):42660-7 – reference: 22000009 - Cell. 2011 Oct 14;147(2):275-92 – reference: 16899222 - Biochem Biophys Res Commun. 2006 Sep 29;348(3):832-8 – reference: 19683746 - J Urol. 2009 Oct;182(4):1621-7 – reference: 16026420 - Acta Physiol Scand. 2005 Aug;184(4):285-93 – reference: 16229833 - Exp Mol Pathol. 2005 Dec;79(3):187-93 |
SSID | ssj0061919 |
Score | 2.3355305 |
Snippet | Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by... Doc number: 32 Abstract Background: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue,... BACKGROUND: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often... Abstract Background Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often... |
SourceID | doaj pubmedcentral biomedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 32 |
SubjectTerms | Adipose tissue Adipose Tissue - enzymology Adipose Tissue - pathology Aged Aggressiveness Body fat Cell line Cell Proliferation Cell tracking Culture Media, Conditioned Humans In Vitro Techniques Male Matrix Metalloproteinase 2 - metabolism Matrix Metalloproteinase 9 - metabolism Medical research Obesity Obesity - pathology Oncology Periprostatic Prostate cancer Prostatic Neoplasms - enzymology Prostatic Neoplasms - pathology Rodents |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQD4gLojzTlspIHLgsjd-2OEFFVSGVC1TqzfITIlWbKNny-xl7nSjLQ1y4-qH1jscz3_jxDUKvQ9nZZyF2LjoJAQoxnZ8H2mWRE41MRE3K4-Srz_Lymn-6ETd7qb7KnbCRHngU3FkmSpsUs2SR80y4Z5wbGpzmLIPvTMX6gs_bBlOjDYaooKb0AN8ou4LoG6kP0fJsVwbmp6tZR_Yfut9O_FOl8f8T9vz1CuWeT7p4hB42MInfjz9xiO6l_jG6f9WOy5-gL3WLHhcy41V53VHYWbGLi9Vyk_BQRY5X9T5e2uDWIuFQFGGN3bcaijdriBc9_rEY1sun6Pri49fzy65lUei81HTotEsapB-y8lTkKITWgMoUly4DegG4EYL2EKnOnTeRcsmjUFQwL5KKPGjHnqGDftmnFwgLaBGd8loSx_08m-QcB8vtwNESqugMvZvI0q5GxgxbOKynNbCcbJkJW2bCMmIZ9H67lbwNjaC85Mm4tTVQ0fL3Dm92HbZf-mvTD2UqJwOqBaBqtqma_ZeqzdDJVhFsW-kbW1KjE1mA0gy92lXDGi0HL65Py7uxjQEkpWEcz0e92Y2kEPoZcFczpCYaNRnqtKZffK884IwpY_j86H_82zF6AFCQ1jtJ9AQdDOu79BLg1uBP68r6CU5LKKU priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection (NC LIVE) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4s1CQUbiwCV0Yzu2Iw4IEFWFVC5QaW-Wn2WlKgm7Kb-fGa83NLyusa2MPOOZb_z4hpCXHnf2uQ-VDVZCglK3lVt6VqUmRRZ4E3SNj5NPP8uTM_Fp1azKhtu2XKvc-8TsqEPvcY_8CEtQ1xID0tvhe4VVo_B0tZTQuE5uIHUZWrVaTQkX5Aa5sAdESFkhri_UPrWWR9M3cEJVrj1y9bn7xSxKZTL_vyHQ3y9SXolMx3fI7QIp6budDdwl12J3j9w8LYfm98mXvFFPkdJ4wDceyNFKbVgP_TbSMU88HfKtvLilpUekHs1hQ-15TsiLT6Trjv5Yj5v-ATk7_vj1w0lVailUTmo2VtpGDTrwSTnWpNA0WgM2U0LaBBgGQIf32kG-urSuDUxIERrFGu6aqILw2vKH5KDru_iY0AZ6BKuclrUVbpnaaK0A_20h3NZMsQV5M5tLM-x4MwwyWc9bQMEGNWFQE4bXhsPo1_uZN77QlGO1jAuT0xUt_xzwahqw_9M_u75HVc4Eyh_6zbkpK9WkWuk2hiR5ECLVwnEhWuatFjwBWIsLcrg3BFPW-9b8ss4FeTE1w0rF4xfbxf5y16cFPKVBjkc7u5kkQVq_FoLWgqiZRc1Enbd062-ZDZxz1bZi-eT_Yj0ltwDqsXzniB2Sg3FzGZ8BnBrd87xmfgIcOSAj priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-kBfFFrJ9nq6zggy-pl_0OUoqKpQjnix70bdnPenAk11wq9r93di8XTT19zc4mw87Xb7K7Mwi9dunPPnW-MN4ISFDKqrBTR4rIYyCecq_KdDl59kWcz9nnC37xux1Qv4Drnald6ic1b5fHP69uTsHgT7LBK_EWIqAoEm4Hh1JQ8Mf7EJZkamcwY8OWAiQKucvHQNzX-dnxglt335ejkJUr---Co7dPVf4Rps4eoPs9vsTvNwpxgO6E-iG6O-t30B-hr_mvPU71jVfpwkcq2IqNX6yadcBdlgJe5SN6YY17ioBd0o0Wm8ucnfcOEi9q_GPRtc1jND_79O3jedE3ViisUKQrlAkKBOKitIRHz7lSANQkEyYCoAEE4pyykLxOja08YYJ5LgmnlgfpmVOGPkF7dVOHZwhzoPBGWiVKw-w0VsEYBs7cQOwtiSQT9G60lnq1KaKhU1nr8QhYmE6S0EkSmpaawuzj7cpr19csT60zljrnLkr8PeHNMGH7pX-SfkiiHDGUHzTtpe7NVsdSqir4KKhnLJbMUsYq4oxiNAJyCxN0tFUEvdVdnbqllyJhpwl6NQyD2aa9GFOH5npDUwG4UsDH043eDJykGn8VRLAJkiONGrE6HqkX33NpcEplVbHp8_-zdYjuAe4j-QASOUJ7XXsdXgC26uzLbDO_AEctIpQ priority: 102 providerName: Scholars Portal |
Title | Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22469146 https://www.proquest.com/docview/1021162181 https://www.proquest.com/docview/1021981282 http://dx.doi.org/10.1186/1756-9966-31-32 https://pubmed.ncbi.nlm.nih.gov/PMC3379940 https://doaj.org/article/f1789edf63d44f14b34492ca843f846e |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELaglRCXijcpJTISBy4LWb-tnhrUqkJKhYBKERfLzxKp2kTJtr-_Y2cT2FBOXHKIx4k145n5xo_PCL33eWWf-lDZYAUUKLWu3MiTKvEUSaA8qDpfTp5ciPNL9mXKp7_Jond28GslPkF-E1VG5RAuKgrRdp8wqOdyYT7-uQm6UAaUNzy2wh2Lzz0_sHOz_bqXkApv_31gc_fM5B9J6OwJOujQIz5Zm_spehCbZ-jRpNsff46-lzV5nNmLF_k6R6ZjxTbMFvNVxG3RMV6UA3hxhTuJiH22_BLbq1J7d-EPzxp8O2uX8xfo8uz0x-fzqns2oXJCkbZSNipQt0_SEZ4C50oBDJNM2ARwBfCF98pBaTqyTgfCBAtcEk4djzIwryx9ifaaeRNfI8xBIljplKgtc6Oko7UMQrWFzFoTSQbouKdLs1hTZJhMWt1vAf8x2RImW8LQ2lDo_XGjeeM7RvL8MMa1KZWJEn93-LDtsPmnf4qOsyl7AypfwNQynVOaVEulY0iCBsZSzRxlTBNvFaMJcFkcoKPNRDCda69Mfgu9FhkZDdC7bTM4Zd5psU2c36xlNEAnBeN4tZ4325FkBj8N-WmAZG9G9Ybab2lmvwrxN6VSazY6_C-tv0GPAfSRcvqIHKG9dnkT3wKwat0QPZRTOUT749OLr9-GZXkCPidMDYuz3QFsliVw |
linkProvider | BioMedCentral |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4s1CASOBxCU0sR3HEUKIV7Wl3V5opb0Zx3bKSlUSdlMQf4rfyIyTLA2vW69-JCPPeL4Zjz1DyBOLJ_vcusg4I8FBSfKoiC2LyrT0zPHUqQQfJ88O5PRIfJin8w3yY3gLg9cqB50YFLWrLZ6Rb2MJ6kQiIL1qvkRYNQqjq0MJjU4s9vz3b-CyrV7uvgP-PmVs5_3h22nUVxWICqlYGynjFVBjy6xgaenSVCmwUjIhTQloDvBrrSrAc4tNkTsmpHBpxlJepD5zwirD4bsXyEUA3hidvWy-dvDAFwmFRACRZYR-RJ9KKFFye90GSi8KtU7OPq8_GaFiKB7wN4v394ubZ5Bw5xq52puw9HUnc9fJhq9ukEuzPkh_k3wMgQGKKZQbfFOCOWGpcYumXnnaBkbTJtwC9Cvaj_DUovgtqTkOBwC9DqaLin5dtMv6Fjk6l1W-TTaruvJ3CU1hhDNZoWRiRBGXuTdGAF4YgPeEZWxCXozWUjddng6NmbPHPSBQGjmhkROaJ5rD7OfDymvbp0XH6hwnOrhHSv454dl6wvCnfw59g6wcERQa6uWx7jWDLpNM5d6VkjshykQUXIicWaMEL8E49BOyNQiC7vXLSv_aDRPyeN0NmgHDPaby9Wk3Jgf7TQEddzq5WVOCaQRzAMkJyUYSNSJ13FMtPofs45xneS7ie_8n6xG5PD2c7ev93YO9--QKmJks3HdiW2SzXZ76B2DKtcXDsH8o-XTeG_Ynwc1cGg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqIlVcEG8WChiJA5e0G7_iiBMFVuXRCgGVKi6W48d21VUS7ab8fsaOs9qUcuK2Wo93rZnx-JvE8w1Cr014sk-NzbTVAhKUvMyqqSGZ594RS7mVeShOPjkVx2fs8zk_30HzoRYmabDx2wT3Q5GgCYpYJRaci4PtAvVljOrwwVwettb3wUCKQzgdRRYwPQSbjEKsvlVwXoRWB9-Pfg0hG5KI2AFkI5w4gG74gWt18cvRcRZZ_2-CqtdvXG4dYbO76E7Cnvhd7yz30I6r76O9k_R2_QH6EZ_o46CRNhSDBDJXrO2ibdYOd9FCuI3X99waJwmHe3VhPY-ZewqeeFHj34tu1TxEZ7OPP98fZ6npQlYJSbpMaifBWMYXFeHeci4lgLiCCe0B7AA6MUZWkNhOdVVawgSzoE5OK-4Ky4zU9BHarZvaPUGYg4TVRSVFrlk19aXTmkGg13Au56QgE_R2pEvV9gQbKlBej0fAuCpYQgVLKJorCrMPBs0rk_jMQ1uNpYp5jRR_T3izmTD80z9Fj4IpRwuKXzSruUpbWvm8kKWzXlDLmM9ZRRkridGSUQ-ozk3Q_uAIKrn1WoVO6rkIuGqCXm2GYUuH9zS6ds1VL1MC8JKwjse932xWEvj_SjjdJqgYedRoqeORenERacMpLcqSTZ_-l9Zfor1vH2bq66fTL8_QbUCPJF5jIvtot1tdueeA0LrqRdxdfwDMKD0h |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+periprostatic+adipose+tissue+promotes+prostate+cancer+aggressiveness+in+vitro&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Ribeiro%2C+Ricardo&rft.au=Monteiro%2C+C%C3%A1tia&rft.au=Cunha%2C+Virg%C3%ADnia&rft.au=Oliveira%2C+Maria+Jos%C3%A9&rft.date=2012-04-02&rft.pub=BioMed+Central&rft.issn=1756-9966&rft.volume=31&rft_id=info:doi/10.1186%2F1756-9966-31-32&rft.externalDocID=2691878671 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |